Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment

被引：1
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [2 ]
机构：
[1] AHEPA Univ Hosp, Dept Internal Med 1, Ctr Diabet Endocrinol & Metab, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
来源：
CURRENT MEDICAL RESEARCH AND OPINION | 2019年 / 35卷 / 07期
关键词：
FATTY LIVER-DISEASE; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR OUTCOMES; STATINS; RISK; BILIRUBIN; LIRAGLUTIDE;
D O I：
10.1080/03007995.2019.1589152
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1305 / 1306
页数：2
相关论文
共 50 条
[41]   Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis [J].
Ahsan, Farah ;
Oliveri, Federico ;
Goud, Harshit K. ;
Mehkari, Zainab ;
Mohammed, Lubna ;
Javed, Moiz ;
Althwanay, Aldanah ;
Rutkofsky, Ian H. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
[42]   Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review) [J].
Bica, Cristina ;
Sandu, Camelia ;
Suceveanu, Andra Iulia ;
Sarbu, Eliza ;
Stoica, Roxana Adriana ;
Gherghiceanu, Florentina ;
Bohiltea, Roxana Elena ;
Stefan, Simona Diana ;
Stoian, Anca Pantea .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (03) :2387-2391
[43]   Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus [J].
Labenz, Christian ;
Kostev, Karel ;
Alqahtani, Saleh A. ;
Galle, Peter R. ;
Schattenberg, Joern M. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2022, 130 (03) :172-177
[44]   Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus [J].
Sumida, Yoshio ;
Seko, Yuya ;
Yoneda, Masashi .
HEPATOLOGY RESEARCH, 2017, 47 (04) :266-280
[45]   Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis [J].
Rakoski, M. O. ;
Singal, A. G. ;
Rogers, M. A. M. ;
Conjeevaram, H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (10) :1211-1221
[46]   Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies [J].
Chen, Hao ;
Zhou, Yang ;
Hao, Haiping ;
Xiong, Jing .
CHINESE JOURNAL OF NATURAL MEDICINES, 2024, 22 (08) :724-745
[47]   Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis [J].
Bandyopadhyay, Sanjay ;
Samajdar, Shambo Samrat ;
Das, Saibal .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (07)
[48]   Hepatic Ceramide May Mediate Brain Insulin Resistance and Neurodegeneration in Type 2 Diabetes and Non-alcoholic Steatohepatitis [J].
Lyn-Cook, Lascelles E. ;
Lawton, Margot ;
Tong, Ming ;
Silbermann, Elizabeth ;
Longato, Lisa ;
Jiao, Ping ;
Mark, Princess ;
Wands, Jack R. ;
Xu, Haiyan ;
de la Monte, Suzanne M. .
JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (04) :715-729
[49]   Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus (Diabetes Metab J 2020;44:267-76) [J].
Yu, Sung Hoon .
DIABETES & METABOLISM JOURNAL, 2020, 44 (03) :482-483
[50]   Non-alcoholic Fatty Liver Disease and Diabetes Mellitus [J].
Khneizer, Gebran ;
Rizvi, Syed ;
Gawrieh, Samer .
DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 :417-440
12345